← Stack Research Tool

Pair page

Argireline with Syn-Ake

Mechanism-tag overlap and published literature for Argireline and Syn-Ake, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.

Mechanism overlap

Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.

ARGIRELINE SYN-AKE 2 UNIQUE TAGS 1 UNIQUE TAGS 0 SHARED
Argireline unique cosmetic-peptidesnap-25-mimetic
Shared none
Syn-Ake unique cosmetic-snake-venom-mimetic

Co-administration notes from the literature

Verbatim summary text pulled from each compound's profile data. Researchers studying Argireline and Syn-Ake have published these mechanism-level observations. Not a co-administration recommendation.

Evidence level: mechanistic only

The flagship "Botox-alternative" cosmetic peptide. Argireline mimics the N-terminus of SNAP-25 and is proposed to interfere with SNARE-complex assembly at the presynaptic motor terminal, while Syn-Ake's claimed mechanism is postsynaptic nAChR antagonism. The two peptides target opposite sides of the neuromuscular junction with complementary mechanisms — one of the most common pairings in "Botox-in-a-jar" finished products. Typical combined formula: 5–10% Argireline + 2–4% Syn-Ake solution + supporting humectants and matrix peptides.

Quick facts

Argireline

RouteTopical only (cosmetic)
Half-lifeNot listed
FDA statusCosmetic ingredient (not a drug)
WADAN/A (topical cosmetic)
Full Argireline profile →

Syn-Ake

RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient (not drug-approved)
WADANot banned
Full Syn-Ake profile →

Literature table

Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.

Year Compound Source Finding
2025ArgirelineZdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025 Jun 14;26(12):5722. doi: 10.3390/ijms26125722. PMID: 40565185. (Most recent systematic review; formulation science is the domin… PMID 40565185systematic review
2019ArgirelineChoi SY, Kwon HJ, Ahn GR, Ko EJ, Yoo KH, Kim BJ, Lee C, Kim D. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Ann Dermatol. 2019 Jun;31(3):263-271. doi: 10.5021/ad.2019.31.3.263.… PMID 33911590human trial
2017ArgirelineRaikou V, Varvaresou A, Panderi I, Papageorgiou E. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. J Cosmet Dermatol. 2017 Jun;16(2):271-278. doi: 10.1111/jocd.12314. PMID: 28150423. (Four-ar… PMID 28150423human trial
2013ArgirelineWang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013 Apr;14(2):147-153. doi: 10.1007/s40257-013-0009-9. PMID: 23417317. (The largest ran… PMID 23417317human trial
2013ArgirelineLungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013 Mar;20(3):515-518. doi: 10.1111/ene.12009. PMID: 23146065. (NIH / NIN… PMID 23146065human trial
2002ArgirelineBlanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-310. doi: 10.1046/j.1467-2494.2002.00153.x. PMID: 184985… PMID 18498523human pilot
2013ArgirelineWang Y, Wang M, Xiao XS, Pan P, Li P, Huo J. The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects. J Cosmet Laser Ther. 2013 Aug;15(4):237-241. doi: 10.3109/14764172.2013.769273. PMID: 23607739. (Companion murine / clinical paper — D-galactose-aged… PMID 23607739preclinical, in vivo
2015ArgirelineKraeling MEK, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015 Mar;34(1):46-52. doi: 10.3109/15569527.2014.894521. PMID: 24754410. (Independent FDA in vitro penetration study — ~0.22% of 10% appl… PMID 24754410preclinical, in vitro
2021ArgirelineLim SH, Kathuria H, Amir MHB, Zhang X, Duong HTT, Ho PCL, Kang L. High resolution photopolymer for 3D printing of personalised microneedle for transdermal delivery of anti-wrinkle small peptide. J Control Release. 2021 Jan 10;329:907-918. doi: 10.1016/j.jconrel.2020.10.021. PMID… PMID 33068646pharmacology
2020ArgirelineErrante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020 Oct 26;8:572923. doi: 10.3389/fchem.2020.572923. PMID: 33195060. (Contextual review of cosmetic-peptide biochemistry and categorisation;… PMID 33195060review
2024ArgirelinePublic Interest in Acetyl Hexapeptide-8: Longitudinal Analysis. JMIR Dermatol. 2024;7:e54217. doi: 10.2196/54217. PMID: 38376906. (Google Trends analysis 2013-2023; post-2022 TikTok-driven consumer search surge; coining of "Botox in a bottle" in popular culture.) PMID 38376906research article
2020ArgirelineLim SH, Tiew WJ, Zhang J, Ho PC, Kachouie NN, Kang L. Geometrical optimisation of a personalised microneedle eye patch for transdermal delivery of anti-wrinkle small peptide. Biofabrication. 2020;12(3):035003. doi: 10.1088/1758-5090/ab6d37. PMID: 31952064. (3D-printed personalis… PMID 31952064research article
2012Syn-AkeBeer K, Waibel J. Botulinum toxin type A enhances the duration of clinical effect of topically applied Acetyl Hexapeptide-8 in patients with blepharospasm. (Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Thera…human pilot
1995Syn-AkeTsai MC, Hsieh WH, Smith LA, Lee CY. Effects of waglerin-I on neuromuscular transmission of mouse nerve-muscle preparations. Toxicon. 1995;33(3):363-371. PMID: 7638875. PMID 7638875preclinical, in vivo
1992Syn-AkeAiken SP, Sellin LC, Schmidt JJ, Weinstein SA, McArdle JJ. A novel peptide toxin from Trimeresurus wagleri acts pre- and post-synaptically to block transmission at the rat neuromuscular junction. Pharmacol Toxicol. 1992;70(6 Pt 1):459-462. PMID: 1359525. PMID 1359525preclinical, in vivo
1991Syn-AkeWeinstein SA, Schmidt JJ, Bernheimer AW, Smith LA. Characterization and amino acid sequences of two lethal peptides isolated from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1991;29(2):227-236. PMID: 2048140. PMID 2048140mechanism / discovery
2025Syn-AkeAcetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Cosmetics. 2025; PMC12193160. (Recent review of the most-studied class analog, evaluating skin permeation barriers — directly applicable to interpreting realistic Syn-Ake efficacy ceilings.)review
2022Syn-AkeAnti-ageing peptides and proteins for topical applications: a review. Pharm Dev Technol. 2022;27(1):108-125. PMID: 34957891. (Recent comprehensive review of topical anti-aging peptides including discussion of nAChR-antagonist class members.) PMID 34957891review
Syn-AkeWikipedia / scholarly venomic summary: Tropidolaemus wagleri . Note: While T. wagleri 's waglerin-1 selectively blocks the ε-subunit-containing acetylcholine receptor of adult muscle, there is no scientific evidence supporting the manufacturer claim that the much smaller Syn-Ake…industry documentation
2005Syn-AkeLupo MP. Cosmeceutical peptides. Dermatol Surg. 2005;31(7 Pt 2):832-836. PMID: 16029675. PMID 16029675research article
2002Syn-AkeMolles BE, Tsigelny I, Nguyen PD, Gao SX, Sine SM, Taylor P. Residues in the epsilon subunit of the nicotinic acetylcholine receptor interact to confer selectivity of waglerin-1 for the alpha-epsilon subunit interface site. Biochemistry. 2002;41(25):7895-7906. PMID: 12069578. PMID 12069578research article
2002Syn-AkeMolles BE, Rezai P, Kline EF, McArdle JJ, Sine SM, Taylor P. Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors. J Biol Chem. 2002;277(7):5433-5440. PMID: 11724791. PMID 11724791research article
1999Syn-AkeMcArdle JJ, Lentz TL, Witzemann V, Schwarz H, Weinstein SA, Schmidt JJ. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 1999;289(1):543-550. PMID: 10087048. (The pivotal paper establishing waglerin-1's selectiv… PMID 10087048research article
1996Syn-AkeSellin LC, Mattila K, Annila A, Schmidt JJ, McArdle JJ, Hyvönen M, Rauh JJ, Kuusela P. Conformational analysis of a toxic peptide from Trimeresurus wagleri which blocks the nicotinic acetylcholine receptor. Biophys J. 1996;70(1):3-13. PMID: 8770182. PMID 8770182research article

Related pair pages

More research context

Frequently asked

Have Argireline and Syn-Ake been studied together?

Researchers have published mechanistic-level co-administration discussion of Argireline and Syn-Ake. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.

What mechanisms do Argireline and Syn-Ake share?

Argireline and Syn-Ake do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.

What is the FDA status of Argireline and Syn-Ake?

Argireline: Cosmetic ingredient (not a drug). Syn-Ake: Cosmetic ingredient (not drug-approved). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.

Where can I find the full research on Argireline and Syn-Ake?

Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Argireline profile and the Syn-Ake profile. The Kalios Stack Research Tool hub lists every compound covered.

Last updated: April 2026